Fluid overload on acute heart failure, terapeutics from the first world in third world
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9904Keywords:
Heart Failure, DiureticsAbstract
About 90% of the Heart Failure patients are admitted due to congestive symptoms in the emergency departments, this is the leading cause of hospitalization and also a prognostic factor for cardiovascular death. The success of therapy in these patients comes from the proper use of the resources at our disposal.
Objective: Provide relevant knowledge to the clinician for the comprehensive approach to patients with heart failure and fluid overload.
Methodology: Narrative review.
Results: Loop diuretics continue to be the first line of management, reducing mortality rates, but there are also other pharmacological strategies when an adequate response is not achieved, among them we find thiazide diuretics, mineralocorticoid receptor antagonists and in cases of distribution vascular, the use of nitrates and hypertonic saline solution has been described.
Conclusions: The gradual and timely management of diuretic drugs decreases the cost and improves the prognosis of patients with heart failure and fluid overload.
Downloads
References
Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009; 360:1418-28. Doi: 10.1056/NEJMsa0803563.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70:2476-86. Doi: 10.1016/j.jacc.2017.08.074.
de la Espriella R, Santas E, Zegri Reiriz I, Górriz JL, Cobo Marcos M, Núñez J. Cuantificación y tratamiento de la congestión en insuficiencia cardíaca: una visión clínica y fisiopatológica. Nefrología. 2022;42:145-62. Doi: 10.1016/j.nefro.2021.04.006.
Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, et al. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation 2019;140:1369-79. Doi: 10.1161/CIRCULATIONAHA.119.039920.
Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail. 2018;20:1591-600. Doi: 10.1002/ejhf.1307.
Argaiz ER. VExUS Nexus: Bedside Assessment of Venous Congestion. Adv Chronic Kidney Dis. 2021;28:252-61. Doi: 10.1053/j.ackd.2021.03.004.
Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JEA, Cleland JG, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-33. Doi: 10.1093/eurjhf/hfq045.
Rodríguez-Espinosa D, Guzman-Bofarull J, De La Fuente-Mancera JC, Maduell F, Broseta JJ, Farrero M. Multimodal strategies for the diagnosis and management of refractory congestion. an integrated cardiorenal approach. Front Physiol. 2022;13: 913580. doi: 10.3389/fphys.2022.913580..
Miller WL. Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail. 2016;9: e002922.Doi: 10.1161/CIRCHEARTFAILURE.115.002922.
Miller WL, Mullan BP. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. JACC Heart Fail. 2014;2:298-305.Doi: 10.1016/j.jchf.2014.02.007.
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-6.Doi: 10.1056/NEJM197112232852601.
Núñez J, Llàcer P, Bertomeu-González V, Bosch MJ, Merlos P, García-Blas S, et al. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: A randomized study. JACC Heart Fail. 2016;4:833-43.Doi: 10.1016/j.jchf.2016.06.007.
Núñez J, Bayés-Genís A, Revuelta-López E, Ter Maaten JM, Miñana G, Barallat J, et al. Clinical role of ca125 in worsening heart failure: A BIOSTAT-CHF Study subanalysis. JACC Heart Fail. 2020;8:386-97.Doi: 10.1016/j.jchf.2019.12.005.
Mullens W, Damman K, Harjola V-P, Mebazaa A, Brunner-La Rocca H-P, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55.Doi: 10.1002/ejhf.1369.
Márquez L, Luz L. Congestión y su diagnóstico en la insuficiencia cardíaca crónica descompensada. Insufic Cardíaca. 2020;15:106-18.
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.Doi: 10.1056/NEJMoa1005419.
Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042-51.Doi: 10.1016/j.jacc.2017.04.042.
Park JJ, Kim S-H, Oh I-Y, Choi D-J, Park H-A, Cho H-J, et al. The effect of door-to-diuretic time on clinical outcomes in patients with acute heart failure. JACC Heart Fail. 2018;6:286-94.Doi: 10.1016/j.jchf.2017.12.017.
Ellison DH, Felker GM. Diuretic treatment in heart failure--from physiology to clinical trials. N Engl J Med. 2017;377:1964-75.Doi: 10.1056/NEJMra1703100.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726. Doi: 10.1093/eurheartj/ehab368.
Ruggenenti P, Remuzzi G. Worsening kidney function in decompensated heart failure: treat the heart, don’t mind the kidney. Eur Heart J. 2011;32:2476-8.Doi: 10.1093/eurheartj/ehr242.
Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, et al. Multinephron segment diuretic therapy to overcome diuretic resistance in acute heart failure: a single-center experience. J Card Fail. 2022;28:21-31.Doi: 10.1016/j.cardfail.2021.07.016.
Novak JE, Ellison DH. Diuretics in states of volume overload: core curriculum 2022. Am J Kidney Dis Off J Natl Kidney Found. 2022;80:264-76.Doi: 10.1053/j.ajkd.2021.09.029.
Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF Randomized clinical trial. JAMA Cardiol. 2017;2:950-8.Doi: 10.1001/jamacardio.2017.2198.
Núñez J, Heredia R, Payá A, Sanchis I, del Prado S, Miñana G, et al. Use of acetazolamide in the treatment of patients with refractory congestive heart failure. Cardiovasc Ther. 2018;36:e12465.Doi: 10.1111/1755-5922.12465.
Burbano JDO, Giraldo CIS, Marín DAE. Solución salina hipertónica y dosis altas de diurético, ¿qué sabemos y cómo podemos usarlos en congestión persistente? Arch Peru Cardiol Cir Cardiovasc. 2021;2:247-53.Doi: 10.47487/apcyccv.v2i4.159.
Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center’s experience. JACC Heart Fail. 2020;8:199-208.Doi: 10.1016/j.jchf.2019.10.012.
Alzahri MS, Rohra A, Peacock WF. Nitrates as a treatment of acute heart failure. Card Fail Rev. 2016;2:51-5.Doi: 10.15420/cfr.2016:3:3.
Downloads
Published
Versions
- 2023-03-29 (2)
- 2022-12-30 (1)
Issue
Section
License
Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
